Stock Quote Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Markets Stocks ETFs Tools Overview News Currencies International Treasuries Amryt Pharma Plc ADR (NQ: AMYT ) 14.70 UNCHANGED Last Price Updated: 4:00 PM EDT, Apr 11, 2023 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 0 Open 14.70 Bid (Size) 14.63 (8) Ask (Size) 14.90 (1) Prev. Close 14.70 Today's Range 14.70 - 14.70 52wk Range 6.500 - 14.77 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc April 12, 2023 From Amryt Pharma plc Via GlobeNewswire High Court of Justice of England and Wales Sanctions Scheme of Arrangement April 03, 2023 From Amryt Pharma plc Via GlobeNewswire Performance YTD +103.04% +103.04% 1 Month N/A N/A 3 Month N/A N/A 6 Month +0.75% +0.75% 1 Year +107.04% +107.04% More News Read More Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici March 22, 2023 From Amryt Pharma plc Via GlobeNewswire Top 5 Health Care Stocks That Are Ticking Portfolio Bombs March 14, 2023 Via Benzinga AMYT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Amryt Pharma Plc Is Fair to Shareholders February 27, 2023 From Halper Sadeh LLC Via Business Wire Why Shares of Amryt Pharma Jumped This Week January 12, 2023 Via The Motley Fool AMRYT PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amryt Pharma Plc - AMYT February 24, 2023 From Kahn Swick & Foti, LLC Via Business Wire AMRYT PUBLISHES SCHEME CIRCULAR AND ANNOUNCES THE SHAREHOLDER MEETINGS TO CONSIDER AND VOTE ON THE CHIESI ACQUISITION WILL BE HELD ON MARCH 22, 2023 February 16, 2023 From Amryt Pharma plc Via GlobeNewswire AMRYT PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amryt Pharma Plc - AMYT January 10, 2023 From Kahn Swick & Foti, LLC Via Business Wire Benzinga's Top Ratings Upgrades, Downgrades For January 18, 2023 January 18, 2023 Via Benzinga S&P 500 Gains 0.6%; Albireo Pharma Shares Spike Higher January 09, 2023 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For January 10, 2023 January 10, 2023 Via Benzinga Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session January 09, 2023 Via Benzinga 12 Health Care Stocks Moving In Monday's Intraday Session January 09, 2023 Via Benzinga Nasdaq Surges Over 200 Points; Crude Oil Rises 2% January 09, 2023 Via Benzinga Tesla, Zillow, Albireo Pharma And Some Other Big Stocks Moving Higher On Monday January 09, 2023 Via Benzinga US Stocks Open Higher; Dow Rises 150 Points January 09, 2023 Via Benzinga AMYT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Amryt Pharma Plc Is Fair to Shareholders January 09, 2023 From Halper Sadeh LLC Via Business Wire Benzinga's Top Ratings Upgrades, Downgrades For January 9, 2023 January 09, 2023 Via Benzinga Adobe To Rally 25%? Here Are 10 Other Analyst Forecasts For Monday January 09, 2023 Via Benzinga Italian Privately Held Chiesi Farmaceutici To Acquire Amryt Pharma For $1.25B January 09, 2023 Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session January 09, 2023 Via Benzinga Why CinCor Pharma Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving Premarket January 09, 2023 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday January 09, 2023 Via InvestorPlace Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc January 08, 2023 From Amryt Pharma plc Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.